—
Kyowa Fermentation Bio Co., Ltd. announced that it has transferred all shares of Kyowa Pharma Chemical Co., Ltd. to Dai Nippon Printing Co., Ltd., and the transfer was completed as of October 1, 2026. For information on the impact on the consolidated group's performance, please refer to Kirin Holdings Co., Ltd.'s IR release dated the same day.
On July 15, 2026, a share transfer agreement was signed concerning the shares of Kyowa Pharma Chemical Co., Ltd. The execution of the share transfer is scheduled for the fourth quarter of 2026.
Kyowa Fermentation Bio has been certified as a Health Management Excellence Corporation 2026 (Large Enterprise Division) by the Ministry of Economy, Trade and Industry and the Japan Health Conference. This certification marks six consecutive years. The company promotes flexible work styles and works on employee mental health and prevention of lifestyle diseases.
Kyowa Fermentation Bio Co., Ltd. will relocate its headquarters to 1-1 Kyowa-cho, Bofu-shi, Yamaguchi Prefecture, effective April 1, 2026. Some departments, such as the Sales and Marketing Department, will continue to operate from the Tokyo office at the Kiling Group headquarters. There will be no changes to the registered head office address or the representative telephone number.
Kyowa Fermentation Bio Co., Ltd. announced that Mr. Hiroshi Nagano has taken office as President and CEO, and Mr. Koji Fukada has resigned. Mr. Kazushi Nagashima and Mr. Daiji Nii have been appointed as part-time directors, and Mr. Toshiharu Miyata has been transferred to part-time auditor. Additionally, Mr. Osamu Hara has resigned as full-time auditor.
Kyoei Fermentation Bio announced that it has completed the transfer of its amino acid and human milk oligosaccharide (HMO) businesses to a special purpose company, a subsidiary of Meihua Holdings Group Co., Ltd., effective July 1, 2025.
Kirin Holdings announced that it had received reports of emails posing as the previously used email address "[email protected]." The address is no longer in use, and the email headers may have been tampered with. The company urges recipients not to reply to unfamiliar emails and not to visit the website listed in the message.
Kyowa Fermentation Bio has been certified as a Health Management Excellence Corporation 2025 (Large Enterprise Division) by the Ministry of Economy, Trade and Industry and the Japan Health Conference. This is the company's fifth consecutive year of certification. The company is working on promoting flexible work styles, employee mental health and lifestyle disease prevention, and raising awareness about responsible alcohol consumption.
Kyowa Hakko USA is marking Brain Awareness Week, March 10–16, by highlighting Cognizin® Citicoline. The company describes the science-backed ingredient as supporting focus, memory, attention, and long-term brain health, citing recent scientific findings.
Kyoei Fermentation Bio's human milk oligosaccharide 2FL, manufactured and sold by the company, was approved as a food additive by the Chinese National Health Commission on February 10, 2025. The additive is authorized for use in four categories: infant, toddler, preschool child, and special medical infant formula. The company will commence entry into the Chinese market.